The Migraine Functional Impact Questionnaire (MFIQ) is a reliable a valid measure that can be used to collect data about migraine impact, a new study suggests. Adults with migraine completed the MFIQ as well as additional clinical and patient-reported outcome measures (PRO) instruments. Psychometric properties of the MFIQ were evaluated to assess reliability, validity, and responsiveness. Researchers found:
- 569 adults (median age 39.9 years, 87.2% female, 80.8% white) with migraine were enrolled.
- All scores exhibited higher internal consistency and moderate test-retest reliability among stable participants.
- Construct validity was demonstrated by significant correlations between MFIQ domain scores, related PRO scores, and the frequency of migraine days and headache days.
- Improvements in MFIQ scores corresponded with clinical improvement, improvements in migraine interference with daily activities, and related improvements in PRO scores.
Kawata AK, et al. Evaluating the psychometric properties of the Migraine Functional Impact Questionnaire (MFIQ). [Published online ahead of print June 5, 2019]. Headache. doi:10.1111/head.13569.
In December 2009, the US Food and Drug Administration (FDA) published a 43-page detailed guidance for development of patient-reported outcome measures (PROs) (www.fda.gov/media/77832/download). Since then, the Migraine Physical Function Impact Diary (MPFID) was developed as a daily recording of multiple domains in patient functioning and outcomes. MPFID yielded highly reliable data because of its daily data gathering, but daily diaries are not practical clinically. Other frequently used PROs include the Headache Impact Test (HIT-6) and the Migraine Disability Assessment scale (MIDAS), which require recollection on events across 1-month or 3-months respectively, and thus have some drawbacks. Existing PROs fall short in evaluating “acts (things that an individual can do independent of context or purpose) and tasks (things people do in daily life in a specific context, with purpose).” These investigators created and validated a new PRO, the Migraine Functional Impact Questionnaire (MFIQ) in order to improve on currently available PROs and reduce recall to 1-week. —Stewart J. Tepper, MD, FAHS, Professor of Neurology, Geisel School of Medicine at Dartmouth, Director, Dartmouth Headache Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH